Evidence map›Paper›PMID 27810310›Full record

Trial reportEBioMedicine2016

Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial.

Lotta K Stenman, Markus J Lehtinen, Nils Meland, Jeffrey E Christensen, Nicolas Yeung, Markku T Saarinen, Michael Courtney, Rémy Burcelin, Marja-Leena Lähdeaho, Jüri Linros and 5 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05710055 (A Randomized, Double-blind, Controlled Trial to Evaluate the Efficacy on Overweight With Oral Supplemenation of Probiotics and Prebiotics), which is not on this map. Cited by 89 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 11 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05710055 nacompletednot on this mapstarted 2023, after this paper: background citation

A Randomized, Double-blind, Controlled Trial to Evaluate the Efficacy on Overweight With Oral Supplemenation of Probiotics and Prebiotics

TypeinterventionalSponsorShenzhen Precision Health Food Technology Co. Ltd.,Ran2023 to 2023Enrolled200ConditionsOverweightArmsStudy product A (Wonderlab wonder4shape), Study product B (Wonderlab wonder4shape), Study product C (Wonderlab wonder4shape), Study product D
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 11 syntheses or guidelines pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Lotta K StenmanGlobal Health and Nutrition Science, DuPont Nutrition & Health, FI-02460 Kantvik, Finland. Electronic address: lotta.stenman@dupont.com.
Markus J LehtinenGlobal Health and Nutrition Science, DuPont Nutrition & Health, FI-02460 Kantvik, Finland.
Nils MelandSmerud Medical Research, N-0212 Oslo, Norway.
Jeffrey E ChristensenVaiomer S.A.S, FR-31670 Labège, France.
Nicolas YeungGlobal Health and Nutrition Science, DuPont Nutrition & Health, FI-02460 Kantvik, Finland.
Markku T SaarinenGlobal Health and Nutrition Science, DuPont Nutrition & Health, FI-02460 Kantvik, Finland.
Michael CourtneyVaiomer S.A.S, FR-31670 Labège, France.
Rémy BurcelinVaiomer S.A.S, FR-31670 Labège, France.
Marja-Leena LähdeahoFinnMedi, FI-33520 Tampere, Finland.
Jüri LinrosKerava Health Centre, FI-04200 Kerava, Finland.
Dan ApterVL-Medi, FI-00101 Helsinki, Finland.
Mika ScheininClinical Research Services Turku, FI-20520 Turku, Finland.
Hilde Kloster SmerudSmerud Medical Research, N-0212 Oslo, Norway.
Aila RissanenObesity Research Unit, University of Helsinki, FI-00290 Helsinki, Finland.
Sampo LahtinenGlobal Health and Nutrition Science, DuPont Nutrition & Health, FI-02460 Kantvik, Finland.
DuPont (Finland) · FISmerud Medical Research (Norway) · NOAava Medical Centre · FIFinnMedi (Finland) · FIUniversity of Helsinki · FIVL-Medi Oy (Finland) · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe gut microbiota is interlinked with obesity, but direct evidence of effects of its modulation on body fat mass is still scarce. We investigated the possible effects of Bifidobacterium animalisssp. lactis 420 (B420) and the dietary fiber Litesse® Ultra polydextrose (LU) on body fat mass and other obesity-related parameters.

methods225 healthy volunteers (healthy, BMI 28-34.9) were randomized into four groups (1:1:1:1), using a computer-generated sequence, for 6months of double-blind, parallel treatment: 1) Placebo, microcrystalline cellulose, 12g/d; 2) LU, 12g/d; 3) B420, 10

findingsThere were marked differences in the results of the Intention-To-Treat (ITT; n=209) and Per Protocol (PP; n=134) study populations. The PP analysis included only those participants who completed the intervention with >80% product compliance and no antibiotic use. In addition, three participants were excluded from DXA analyses for PP due to a long delay between the end of intervention and the last DXA measurement. There were no significant differences between groups in body fat mass in the ITT population. However, LU+B420 and B420 seemed to improve weight management in the PP population. For relative change in body fat mass, LU+B420 showed a-4.5% (-1.4kg, P=0.02, N=37) difference to the Placebo group, whereas LU (+0.3%, P=1.00, N=35) and B420 (-3.0%, P=0.28, N=24) alone had no effect (overall ANOVA P=0.095, Placebo N=35). A post-hoc factorial analysis was significant for B420 (-4.0%, P=0.002 vs. Placebo). Changes in fat mass were most pronounced in the abdominal region, and were reflected by similar changes in waist circumference. B420 and LU+B420 also significantly reduced energy intake compared to Placebo. Changes in blood zonulin levels and hsCRP were associated with corresponding changes in trunk fat mass in the LU+B420 group and in the overall population. There were no differences between groups in the incidence of adverse events. DISCUSSION: This clinical trial demonstrates that a probiotic product with or without dietary fiber controls body fat mass. B420 and LU+B420 also reduced waist circumference and food intake, whereas LU alone had no effect on the measured outcomes.

Indexed as

Dietary FiberProbioticsAdipose TissueAdultBiomarkersBody CompositionBody Mass IndexCholera ToxinFemaleGastrointestinal MicrobiomeHaptoglobinsHealthy VolunteersHumansMaleMiddle AgedObesityBiomarkersCholera ToxinDietary FiberHaptoglobinsProtein PrecursorszonulinClinical trialFiberObesityPrebioticProbioticSynbiotic

Identifiers

PMID27810310
PMCPMC5264483
OpenAlexW2545199093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.